From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: Lauflumide
Chemical Nomenclature
Common names Flmodafinil, Flodafinil, Fluoromodafinil, Bisfluoromodafinil
Substitutive name Lauflumide
Systematic name 2-[Bis(4-fluorophenyl)methylsulfinyl]acetamide
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 20 mg
Light 20 - 40 mg
Common 40 - 75 mg
Strong 75 - 110 mg
Heavy 110 mg +
Total 8 - 12 hours
Onset 15 - 30 minutes
Come up 30 - 60 minutes
Peak 3 - 6 hours
Offset 1 - 2 hours
After effects 1 - 8 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Lauflumide (also known as CRL-40,940 or commonly as Flmodafinil) is a eugeroic substance of the benzyhydryl chemical class that produces wakefulness and stimulation when administered. It is structurally similar to modafinil, which is used to enhance cognition, reduce fatigue, and increase alertness.

In medicine, eugeroic compounds are used in the treatment of certain sleeping disorders, such as excessive daytime sleepiness and narcolepsy. The prototypical and most widely used eugeroic is modafinil. Both modafinil and its enantiopure formulation, armodafinil, have been found to act as selective, weak, atypical dopamine reuptake inhibitors.[1][2] Unlike traditional stimulants such as amphetamine or methylphenidate, eugeroics are considered to have a low addictive and abuse potential.


Lauflumide is a synthetic molecule of the benzhydryl chemical class. Benzhydryl compounds are comprised of two benzene rings attached to a single carbon molecule. Lauflumide is classified as a sulphinyl benzhydryl molecule, as it also contains a sulphinyl group, a sulfur molecule double-bonded to an oxygen molecule, attached to the carbon of the benzhydryl group. From this sulfur group at R2, an acetamide group is bound at its free carbon through a carbonyl group to a terminal amine group. Lauflumide is structurally analogous to fluorafinil, another benzhydryl eugeroic.

?? is Lauflumide also a racemat? no literature on that ??

?? can Modafinil/Pharmacology be used here? it would be an interesting base for research ??


Lauflumide is a dopamine reuptake inhibitor. It has a lower affinity for DAT receptors than modafinil.

Subjective effects

In comparison to traditional stimulants such as amphetamine, methylphenidate or cocaine, this compound produces an experience which is far less forceful, recreational and euphoric. It instead focuses on general wakefulness and motivation enhancement. Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Cognitive effects

Toxicity and harm potential

The long-term safety and effectiveness of Lauflumide as a drug of regular usage have not been determined.[4]

Anecdotal reports from those who have tried lauflumide suggest that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed).

It is worth noting, however, that as this compound is a commonly prescribed pharmaceutical, it is considerably less likely to have unpredictable adverse health effects than the typical research chemical. Nevertheless, it is strongly recommended that one use harm reduction practices if choosing to use this substance.

Lethal dosage

The LD50 of lauflumide is higher than 1024 mg/kg in mice.[5]

Tolerance and addiction potential

Lauflumide has been reported to have some addiction potential

Tolerance to many of the effects of Lauflumide has been reported to develop after a short time (1-2 weeks) of consistent use.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

  • 25x-NBOMe & 25x-NBOH - 25x compounds are highly stimulating and physically straining. Combinations with Lauflumide should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
  • Alcohol - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
  • DXM - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
  • MDMA - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
  • MXE - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
  • Dissociatives - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
  • Stimulants - Lauflumide may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
  • Tramadol - Tramadol is known to lower the seizure threshold[6] and combinations with stimulants may further increase this risk.
  • MDMA - The neurotoxic effects of MDMA may be increased when combined with other stimulants.
  • MAOIs - This combination may increase the amount of neurotransmitters such as dopamine to dangerous or even fatal levels. Examples include syrian rue, banisteriopsis caapi, and some antidepressants.[7]

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

?? add text that Lauflumide is non scheduled globally ??

  • ??: ?? Not aware of any country having made it illegal, need research ??

See also

External links


  1. "Provigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. January 2015. Retrieved 16 August 2015.
  2. "Nuvigil: Prescribing information" (PDF). United States Food and Drug Administration. Cephalon, Inc. April 2015. Retrieved 16 August 2015.
  3. Udert, K. M., Larsen, T. A., & Gujer, W. (2006). Fate of major compounds in source-separated urine. Water Science and Technology, 54(11–12), 413–420.
  4. Pharmacotherapy for excessive daytime sleepiness |
  6. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183. 
  7. Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210Freely accessible. eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647.